Here's a comment from a competing website where the author originally misspelled "Bempeg" as "Bemped". (what an idiot) .......... .......... "Turning cold tumor "hot" is one objective of EVT801. That's basically the same thing objective that the now-discarded Bemped had. Bad news for Nektar is good news for Kazia, the way I see it. From Cancer Discovery (2020): "As low tumor PD-L1 expression, low levels of baseline tumor-infiltrating lymphocytes (TIL), and absence of a T-cell inflamed tumor microenvironment can be associated with a poor response to CPI (7–10), novel therapeutic approaches that stimulate T cells or overcome T-cell exhaustion may complement or synergize with checkpoint inhibition to achieve durable responses for more patients." So that was the rationale for Bemped trials. I feel for Nektar investors, but maybe they'll now be made aware of EVT801 and Kazia." ............ ............ (Bempeg was being trialed with the checkpoint inhibitor Opdivo and the trials have now been quit by BMY.)
KZA Price at posting:
$1.13 Sentiment: Buy Disclosure: Held
